Mainz BioMed (NASDAQ: MYNZ)
@MainzBioMed
Followers
4K
Following
184
Media
281
Statuses
374
Mainz BioMed (NASDAQ: $MYNZ) develops market-ready molecular genetic diagnostic solutions for life-threatening conditions, such as #colorectal cancer.
Mainz, Germany
Joined November 2021
$MYNZ launches its updated ColoAlert version for CRC screening, featuring a new DNA stabilizing buffer which significantly enhances the lab efficiency. Faster results and fewer retests! #stockmarketnews #investing.
12
5
51
ColoAlert® has received Swissmedic approval ✅. Thanks to our partnership with labor team w ag, our non-invasive, highly sensitive test is now available in Switzerland — to change the reality that only 50% of eligible adults get screened for colorectal cancer. Read more here:
0
1
5
🤝We’re partnering with CARE, a German diagnostics company working with 15+ health insurers to provide online colorectal cancer screening using the FIT test. Together, we’re expanding access to advanced early detection with ColoAlert®. #stocks #investors #stockmarkets
0
0
5
Mainz Biomed made strong H1 2025 progress in early cancer detection:. Launched eAArly DETECT 2 (2,000 pts), setting up 2026 FDA CRC trial. ColoAlert® launched in Switzerland (labor team w ag), expanded in UK (EDX Medical). Advanced pancreatic cancer program: licensed Liquid
2
1
7
Big news! Mainz Biomed secured public funding from Investitions- und Strukturbank Rheinland-Pfalz (ISB), covering 50% of costs to advance their non-invasive blood test for early pancreatic cancer detection. Learn more: #Cancer #CancerResearch
1
3
8
We’ve begun the feasibility phase of PancAlert, validating a biomarker panel with 95% sensitivity and 98% specificity in partnership with Crown bioscience. This step tests assay accuracy, reproducibility, and risk stratification—key for FDA. Learn more:
0
1
9
eAArly DETECT 2 Clinical Study Update . 🗓️Interim read out by Summer 2025!. Goal: Validate next-gen test for early colon cancer detection. 🔬 Detecting polyps & precancerous adenomas. 🗓 Top-line results: Q4 2025.🇺🇸 Potential U.S. trial: 2026. Stay tuned and learn more here:
1
0
1
Mainz Biomed and EDX Medical have joined forces. 🤝A strategic partnership to bring advanced molecular diagnostics to the UK. Learn more: #stocks #investors #stockmarkets #UnitedKingdom #CancerPrevention #Cancer #Health #Medical $Nasdaq $MYNZ
1
2
35
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval. Read the full update here: $MYNZ #INVESTING #NASDAQ #GROWTH
2
1
8
Mainz Biomed 2024 Highlights. 📈 Lab network revenue increased by 33% year over year. 📉Operating loss decreased by 30% and net loss by 18%. 🤝 New partnerships with Thermo Fisher, Quest Diagnostics, and Liquid Biosciences. 💡Key moments: 📊ASCO 2024: Key colorectal cancer data
8
1
58
Mainz Biomed enrolls the first patient in its eAArly DETECT 2 study. 🔬 2,000+ average-risk patients. ✅ Validates previous results. 🛡️ Aims to shift from CRC screening to prevention. 🇺🇸 Supports future U.S. programs. 📅 Top-line results expected Q4 2025. Learn more:
1
1
58
Mainz Biomed & Liquid Biosciences announce groundbreaking discovery of mRNA biomarkers for blood-based detection of #pancreatic cancer. 🧪Discovery analysis: 95% sensitivity AND 98% specificity. 📄 Mainz Biomed signs exclusive license & option agreement for the biomarker
2
2
15
This March, we stand against colorectal cancer. Early detection saves lives. With accessible at-home testing, we help more people get tested — because every life is worth protecting. Learn more: #Cancer #CancerAwareness #cancerai #Science #innovation
2
3
11
Saving lives through early detection! 🇨🇭.Mainz Biomed partners with Labor Team W AG to introduce ColoAlert®—a non-invasive, DNA-based colorectal cancer screening test— in Switzerland. Early detection saves lives. Easier screening = More lives saved. Learn more :
2
2
13
Preventing one of the deadliest preventable cancers! In partnership with GANZIMMUN Diagnostics, our enhanced ColoAlert test is now available across Germany for early detection. Learn more: $MYNZ #StockMarket #investoropportunity #Investor #Innovation
82
2
162
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements . Learn more: #StockMarkets #investing #growthstock #Growth #investor #investoropportunity #NASDAQ #CancerResearch $MYNZ
0
1
7
Mainz Biomed initiates the eAArly DETECT 2 U.S. study to evaluate its next-gen test for advanced adenomas in 2,000 average-risk patients. Enrollment ends mid-2025, with results expected in Q4 2025. Learn more: $MYNZ #StockMarket #StockAlert #GrowthStock
2
120
142
Mainz Biomed partners with Quest Diagnostics for clinical trials of its FDA-validation colorectal cancer test. Learn more: $MYNZ $DGX #StockMarket #StockMarketUpdate #Investors #Investoropportunity #FDA #GrowthStock #Biomed
3
4
18
$MYNZ Mainz Biomed announces a stock split effective Dec. 3, 2024, to increase market price, meet Nasdaq standards, and enhance investor appeal. Read the full press release: #StockMarketNews #StockMarketToday #StockUpdate #stocksplit #investor
9
2
7
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets. Learn more : $TMO $MYNZ #StockMaketNews #Nasdaq #GrowthStock #Biotech #undervalued
3
15
52